Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study

Table 1 Baseline characteristics

Parameter		(N = 486)
Weight (kg)	N (missing)	486 (0)
Mean (SD)		59.8 (8.93)
Median		59.0
Min ~ max		35,105
Height (cm)	N(missing)	486 (0)
Mean (SD)		159.4 (4.58)
Median		160.0
Min ~ max		143,175
BMI (kg/m²)	N(missing)	486 (0)
Mean (SD)		23.5 (3.25)
Median		23.0
Min ~ max		16,39
WHO Performance Status Score	Activities limited	148 (30.5 %)
	Normal activities	329 (67.7 %)
	Bedridden time ≤ 50 %	9 (1.9 %)
	Total	486 (100.0 %)
Primary site	Right breast	240 (49.4 %)
	Left breast	243 (50.0 %)
	Left breast, right breast	3 (0.6 %)
	Total	486 (100.0 %)
Histological type	Invasive carcinoma	463 (95.3 %)
	Carcinoma in-situ	23 (4.7 %)
	Total	486 (100.0 %)
Histological grading	Unevaluable(GX)	58 (11.9 %)
	Poorly differentialted(G3)	84 (17.3 %)
	Well differentiated(G1)	56 (11.5 %)
	Undifferentiated(G4)	9 (1.9 %)
	Moderately differentiated(G2)	279 (57.4 %)
	Total	486 (100.0 %)
ER status	Positive	471 (96.9 %)
	Negative	15 (3.1 %)
	Total	486 (100.0 %)
PR status	Positive	387 (79.6 %)
	Negative	99 (20.4 %)
	Total	486 (100.0 %)
ER and PR status	ER positive,PR positive	372 (76.5 %)
	ER positive,PR negative	99 (20.4 %)
	ER negative,PR positive	15 (3.1 %)
	Total	486 (100.0 %)
Mastectomy	No	36 (7.4 %)
	Yes	450 (92.6 %)
	Total	486 (100.0 %)
Breast-conserving surgery	No	450 (92.6 %)
	Yes	36 (7.4 %)
	Total	486 (100.0 %)
Axillary lymph node dissection	No	103 (21.2 %)
	Yes	383 (78.8 %)
	Total	486 (100.0 %)
Axillary lymph node sampling	No	312 (64.2 %)
	Yes	174 (35.8 %)
	Total	486 (100.0 %)
Prior chemotherapy	No	227 (46.7 %)
	Yes	259 (53.3 %)
	Total	486 (100.0 %)
Prior radiotherapy	No	432 (88.9 %)
	Yes	54 (11.1 %)
	Total	486 (100.0 %)

ISSN: 1477-7525